Vera Therapeutics, Inc.
VERA
$28.82
-$0.48-1.64%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 41.00M | 31.67M | 27.84M | 25.55M | 23.79M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 167.17M | 145.28M | 117.24M | 101.87M | 102.01M |
| Operating Income | -167.17M | -145.28M | -117.24M | -101.87M | -102.01M |
| Income Before Tax | -152.15M | -134.38M | -107.85M | -94.30M | -95.99M |
| Income Tax Expenses | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K |
| Earnings from Continuing Operations | -152.15 | -134.38 | -107.85 | -94.30 | -95.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -152.15M | -134.38M | -107.85M | -94.30M | -95.99M |
| EBIT | -167.17M | -145.28M | -117.24M | -101.87M | -102.01M |
| EBITDA | -134.48M | -112.65M | -84.62M | -70.23M | -70.23M |
| EPS Basic | -2.74 | -2.60 | -2.20 | -2.04 | -2.28 |
| Normalized Basic EPS | -1.71 | -1.62 | -1.38 | -1.28 | -1.43 |
| EPS Diluted | -2.74 | -2.60 | -2.20 | -2.04 | -2.28 |
| Normalized Diluted EPS | -1.71 | -1.62 | -1.38 | -1.28 | -1.43 |
| Average Basic Shares Outstanding | 221.29M | 205.05M | 194.52M | 184.06M | 170.75M |
| Average Diluted Shares Outstanding | 221.29M | 205.05M | 194.52M | 184.06M | 170.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
